JP2023088902A5 - - Google Patents

Download PDF

Info

Publication number
JP2023088902A5
JP2023088902A5 JP2023020149A JP2023020149A JP2023088902A5 JP 2023088902 A5 JP2023088902 A5 JP 2023088902A5 JP 2023020149 A JP2023020149 A JP 2023020149A JP 2023020149 A JP2023020149 A JP 2023020149A JP 2023088902 A5 JP2023088902 A5 JP 2023088902A5
Authority
JP
Japan
Prior art keywords
raav
promoter
seq
cep290
syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023020149A
Other languages
English (en)
Japanese (ja)
Other versions
JP7535332B2 (ja
JP2023088902A (ja
Filing date
Publication date
Priority claimed from JP2019555010A external-priority patent/JP7307480B2/ja
Application filed filed Critical
Publication of JP2023088902A publication Critical patent/JP2023088902A/ja
Publication of JP2023088902A5 publication Critical patent/JP2023088902A5/ja
Application granted granted Critical
Publication of JP7535332B2 publication Critical patent/JP7535332B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023020149A 2017-04-05 2023-02-13 ミニ遺伝子療法 Active JP7535332B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762481727P 2017-04-05 2017-04-05
US62/481,727 2017-04-05
JP2019555010A JP7307480B2 (ja) 2017-04-05 2018-04-05 ミニ遺伝子療法
PCT/US2018/026230 WO2018187552A1 (en) 2017-04-05 2018-04-05 Minigene therapy

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019555010A Division JP7307480B2 (ja) 2017-04-05 2018-04-05 ミニ遺伝子療法

Publications (3)

Publication Number Publication Date
JP2023088902A JP2023088902A (ja) 2023-06-27
JP2023088902A5 true JP2023088902A5 (OSRAM) 2023-10-31
JP7535332B2 JP7535332B2 (ja) 2024-08-16

Family

ID=63712901

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019555010A Active JP7307480B2 (ja) 2017-04-05 2018-04-05 ミニ遺伝子療法
JP2023020149A Active JP7535332B2 (ja) 2017-04-05 2023-02-13 ミニ遺伝子療法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019555010A Active JP7307480B2 (ja) 2017-04-05 2018-04-05 ミニ遺伝子療法

Country Status (7)

Country Link
US (2) US11739346B2 (OSRAM)
EP (1) EP3606544B1 (OSRAM)
JP (2) JP7307480B2 (OSRAM)
CN (2) CN118360335A (OSRAM)
AU (2) AU2018248304C1 (OSRAM)
CA (1) CA3059112A1 (OSRAM)
WO (1) WO2018187552A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016356684C1 (en) * 2015-11-16 2022-11-10 Synlogic Operating Company, Inc. Bacteria engineered to reduce hyperphenylalaninemia
EP3606544B1 (en) 2017-04-05 2025-06-04 University of Massachusetts Minigene therapy
CN114402075A (zh) * 2019-04-19 2022-04-26 马萨诸塞大学 乌谢尔综合征(ush2a)的基因疗法
WO2020214797A1 (en) 2019-04-19 2020-10-22 University Of Massachusetts Gene therapies for usher syndrome (ush1b)
EP3972610B1 (en) * 2019-05-20 2025-09-03 University of Massachusetts Minigene therapy
TW202124722A (zh) 2019-09-18 2021-07-01 美商英特佳樂帝克醫療公司 合成dna載體及其使用方法
WO2022023284A1 (en) 2020-07-27 2022-02-03 Anjarium Biosciences Ag Compositions of dna molecules, methods of making therefor, and methods of use thereof
CN112062827B (zh) * 2020-09-16 2022-10-21 中国人民解放军军事科学院军事医学研究院 Cep55蛋白在调控纤毛去组装和制备纤毛相关疾病模型中的应用
KR20230117177A (ko) * 2020-12-03 2023-08-07 유니버시티 오브 매사추세츠 진행성 골화성 섬유이형성증을 위한 신규 유전자 치료제의개발
WO2022169774A1 (en) * 2021-02-02 2022-08-11 University Of Massachusetts Inverted terminal repeats from aav serotypes 8 and rh.39 in gene therapy vectors

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
US6001650A (en) 1995-08-03 1999-12-14 Avigen, Inc. High-efficiency wild-type-free AAV helper functions
JP2001500015A (ja) 1996-09-06 2001-01-09 トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア T7ポリメラーゼを利用する組換えアデノ随伴ウイルスの誘導可能な製造方法
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
SG168422A1 (en) 2001-11-13 2011-02-28 Univ Pennsylvania A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
WO2009121536A1 (en) 2008-04-02 2009-10-08 Fondazione Telethon Method of treating genetic disorders
US10266845B2 (en) 2013-02-08 2019-04-23 The Trustees Of The University Of Pennsylvania Enhanced AAV-mediated gene transfer for retinal therapies
EP2986635B1 (en) 2013-04-18 2018-10-03 Fondazione Telethon Effective delivery of large genes by dual aav vectors
WO2015009575A1 (en) 2013-07-16 2015-01-22 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of disorders related to cep290
AU2014305218B2 (en) * 2013-08-05 2020-01-16 Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Centrum Recombinant AAV-Crumbs homologue composition and methods for treating LCA-8 and progressive RP
WO2015138510A1 (en) 2014-03-10 2015-09-17 Editas Medicine., Inc. Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10)
WO2016033338A1 (en) * 2014-08-27 2016-03-03 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Methods and compositions for treating leber congenital amaurosis
US10987433B2 (en) 2015-11-19 2021-04-27 The Trustees Of The University Of Pennsylvania Compositions and methods for correction of heritable ocular disease
WO2017108931A1 (en) 2015-12-22 2017-06-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Improved hybrid dual recombinant aav vector systems for gene therapy
US20170348387A1 (en) * 2016-02-29 2017-12-07 The Trustees Of The University Of Pennsylvania Aav-mediated gene therapy for nphp5 lca-ciliopathy
WO2018026976A1 (en) 2016-08-02 2018-02-08 Editas Medicine, Inc. Compositions and methods for treating cep290 associated disease
EP3606544B1 (en) 2017-04-05 2025-06-04 University of Massachusetts Minigene therapy
CN110461368A (zh) 2017-06-30 2019-11-15 加利福尼亚大学董事会 具有变异衣壳的腺相关病毒病毒体及其使用方法
US11723988B2 (en) 2017-10-20 2023-08-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of expressing a polynucleotide of interest in the cone photoreceptors of a subject comprising the subretinal delivery of a therapeutically effective amount of a recombinant AAV9-derived vector
EP3972610B1 (en) 2019-05-20 2025-09-03 University of Massachusetts Minigene therapy

Similar Documents

Publication Publication Date Title
JP2023088902A5 (OSRAM)
JP2020512822A5 (OSRAM)
IL299325B2 (en) Acid-alpha glucosidase variants and uses thereof
US20190309326A1 (en) Dual overlapping adeno-associated viral vector system for expressing abca4
JP2021500922A5 (OSRAM)
JP2017529395A5 (OSRAM)
JP2023522883A (ja) 神経学的障害を処置するための組成物および方法
JPWO2019165050A5 (OSRAM)
JP2022539156A (ja) ヒアルロン酸を用いた眼組織へのaav媒介形質導入の増強
JPWO2020069339A5 (OSRAM)
JPWO2021168362A5 (OSRAM)
JPWO2020186150A5 (OSRAM)
JPWO2021243085A5 (OSRAM)
US20220389450A1 (en) Vector system
JPWO2022026632A5 (OSRAM)
JPWO2021076911A5 (OSRAM)
JPWO2022015715A5 (OSRAM)
JPWO2022031760A5 (OSRAM)
KR102704771B1 (ko) 망막 또는 황반 질환 치료용 조성물
CN121127272A (zh) 用于治疗眼底黄色斑点症的双aav载体
JPWO2020237130A5 (OSRAM)
JPWO2019200286A5 (OSRAM)
CN120400250A (zh) 表达myo7a蛋白的双载体系统及其用途
EP4615492A1 (en) Polynucleotide and vector
AU2023361964A1 (en) Bdnf gene therapy